Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma
Clinical trial NCT04834986 · UNKNOWN
Trial details
- NCT number
- NCT04834986
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-04-30
- Primary completion
- 2022-04-30
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.